The stock of Arcturus Therapeutics Holdings Inc (ARCT) has seen a -13.34% decrease in the past week, with a -18.85% drop in the past month, and a -18.72% decrease in the past quarter. The volatility ratio for the week is 7.87%, and the volatility levels for the past 30 days are at 7.18% for ARCT. The simple moving average for the past 20 days is -11.37% for ARCT’s stock, with a -31.01% simple moving average for the past 200 days.
Is It Worth Investing in Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) Right Now?
The stock has a 36-month beta value of 3.30. Opinions on the stock are mixed, with 8 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ARCT is 24.37M, and at present, short sellers hold a 17.35% of that float. On March 10, 2025, the average trading volume of ARCT was 404.86K shares.
ARCT) stock’s latest price update
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT)’s stock price has gone decline by -8.89 in comparison to its previous close of 15.97, however, the company has experienced a -13.34% decrease in its stock price over the last five trading days. seekingalpha.com reported 2025-03-06 that Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants Neda Safarzadeh – Vice President, Head of Investor Relations Joe Payne – President and Chief Executive Officer, Director of the Board Andy Sassine – Chief Financial Officer Pad Chivukula – Chief Scientific Officer and Chief Operating Officer Conference Call Participants Lili Nsongo – Leerink Yasmeen Rahimi – Piper Sandler Evan Wang – Guggenheim Securities Myles Minter – William Blair Joohwan Kim – Canaccord Genuity Pete Stavropoulos – Cantor Tom Shrader – BTIG Thomas Yip – HCW Yanan Zhu – Wells Fargo Yale Jen – Laidlaw & Company Operator Good day, everyone, and welcome to today’s Arcturus Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Analysts’ Opinion of ARCT
Many brokerage firms have already submitted their reports for ARCT stocks, with BTIG Research repeating the rating for ARCT by listing it as a “Buy.” The predicted price for ARCT in the upcoming period, according to BTIG Research is $41 based on the research report published on January 28, 2025 of the current year 2025.
Leerink Partners, on the other hand, stated in their research note that they expect to see ARCT reach a price target of $70. The rating they have provided for ARCT stocks is “Outperform” according to the report published on August 12th, 2024.
Canaccord Genuity gave a rating of “Buy” to ARCT, setting the target price at $90 in the report published on December 13th of the previous year.
ARCT Trading at -13.81% from the 50-Day Moving Average
After a stumble in the market that brought ARCT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.67% of loss for the given period.
Volatility was left at 7.18%, however, over the last 30 days, the volatility rate increased by 7.87%, as shares sank -15.85% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.01% lower at present.
During the last 5 trading sessions, ARCT fell by -13.34%, which changed the moving average for the period of 200-days by -51.14% in comparison to the 20-day moving average, which settled at $16.42. In addition, Arcturus Therapeutics Holdings Inc saw -14.26% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ARCT starting from Chivukula Pad, who sale 12,000 shares at the price of $20.76 back on Oct 15 ’24. After this action, Chivukula Pad now owns 435,334 shares of Arcturus Therapeutics Holdings Inc, valued at $249,121 using the latest closing price.
Chivukula Pad, the Officer of Arcturus Therapeutics Holdings Inc, proposed sale 12,000 shares at $20.76 during a trade that took place back on Oct 15 ’24, which means that Chivukula Pad is holding shares at $249,121 based on the most recent closing price.
Stock Fundamentals for ARCT
Current profitability levels for the company are sitting at:
- -0.56 for the present operating margin
- 1.05 for the gross margin
The net margin for Arcturus Therapeutics Holdings Inc stands at -0.58. The total capital return value is set at -0.28. Equity return is now at value -31.16, with -20.93 for asset returns.
Based on Arcturus Therapeutics Holdings Inc (ARCT), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -2.09.
Currently, EBITDA for the company is -77.4 million with net debt to EBITDA at 2.99. When we switch over and look at the enterprise to sales, we see a ratio of 1.34. The receivables turnover for the company is 34.82for trailing twelve months and the total asset turnover is 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.67.
Conclusion
To sum up, Arcturus Therapeutics Holdings Inc (ARCT) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
